A new study referencing insulin lispro was published on November 6, 2026. The publication, titled "Drugs Associated with Dementia-Related Adverse Event Reports: A Real World Pharmacovigilance Study," appeared in Revista Brasileira de Psiquiatria.
The study is described as a real world pharmacovigilance analysis. It examines drugs associated with dementia-related adverse event reports. Insulin lispro is named among the drugs covered in this report.
No specific findings, conclusions, or results regarding insulin lispro have been provided beyond the publication title and journal listing. The nature of a pharmacovigilance study is to review adverse event report data, not to establish causation. This brief reports only the existence and bibliographic details of the publication.
Insulin lispro remains an approved compound. Readers interested in the broader context of insulin lispro, including its approved uses and regulatory status, can consult the compound overview for additional background.